Recent workflow advances and novel applications in volumetric microsampling supporting quantitative bioanalysis


A rational approach to device selection is proposed alongside small and large molecule case studies exemplifying novel workflows that eliminate HCT bias, optimize sensitivity and stabilize labile analytes.

In this webinar, an experimental strategy is introduced that aids in microsampling device selection based upon key bioanalytical drivers that consider the relationship between blood hematocrit, collection substrate (rigid porous polymer vs. cellulose), analyte stability and age-related extractability. Exemplary case studies highlighting novel microsampling workflows are then presented for (i) an anti-tuberculosis drug panel requiring pre-treatment of Capitainer®B cellulose substrate to stabilize three reactive analytes and (ii) Fomivirsen, a 21-mer antisense oligonucleotide and its N-1 metabolite, wherein high-yielding extractability with surfactant in a comparability study of Mitra VAMS and Capitainer®B necessitated a hybridization LC-MS/MS approach to overcome matrix complexities.
Of interest to:
​​​​​​​
  1. Scientists developing and validating methods for small and large molecules extracted from dried blood microsamples
  2. Clinical researchers and key decision makers involved with microsampling device selection
  3. Biotech and Pharma groups leveraging microsampling to facilitate drug development
  4. Investigators exploring the patient-centric approach to sample collection
  5. Microsampling manufacturers interested in real world applications and device performance
​​​​​​​​​​​​​​​​​​

Your details

Terms & Conditions

Subscribing to

Confirm sign-up

What you will learn:

  • A bioanalytical-driven strategy for microsample device selection
  • Extraction techniques to overcome HCT-induced recovery bias and age-related extractability
  • Approaches for stabilization of labile analytes via substrate pre-treatment
  • Workflows for extraction and analysis of antisense oligonucleotides from dried blood microsamples
  • Evaluations required for validation of microsampling assays in the regulated space
Speakers:

Jeff Plomley
Scientific Director, Altasciences

Jeff Plomley joined Altasciences in 2016 and currently leads a team of method development scientists tasked with assay development by LC-MS in support of both pre-clinical and clinical programs. Previous roles in mass spectrometry instrumentation following his graduate degree involved scan function design for a variety of platforms resulting in several assigned patents and over 25 publications. Jeff’s current research interests focus on advanced microsampling workflows that align with the rigors of quantitative bioanalysis and the incorporation of ion mobility as an orthogonal gas-phase separation technique for improving assay selectivity.

Mingluan Chen
Principal Research Scientist, Altasciences

Dr Chen holds a PhD in Analytical Chemistry, where his research focused on the quantitative analysis of phytohormones using micro-scale LC-MS. He joined Altasciences in 2014 as a scientist working on small molecule method development and expanded into large molecule method development in 2019. His work focuses on developing novel LC-MS based strategies and workflows for the quantitative bioanalysis of oligonucleotide therapeutics. He has authored more than twenty peer reviewed publications.

Moderated by:

Neil Spooner
Founder, Patient Centric Sampling Interest Group

Located in Hertford, UK, Neil is the Chair and co-founder of the PCSIG. He also runs a consultancy company where one of the main drivers is to help Clients understand the benefits of patient centric blood sampling, develop appropriate technologies and workflows and implement them for the benefit of human wellbeing. Neil’s interest in these technologies began in 2007 whilst leading efforts at GlaxoSmithKline to find blood sampling and analysis approaches suitable for the measurement of pharmaceutical concentrations in samples obtained from children.


Share this webinar